Science Sparks @ ACTREC

Publications
- 1. Mojidra R, Gardi N, Bagal B, Khattry N, Gokarn A, Punatar S, Govekar R (2025). Genomic analysis identifies an incipient signature to forecast imatinib resistance before start of treatment in patients with chronic myeloid leukemia. Advances in Biomarker Sciences and Technology
- 2. Agrawal N, Govekar R (2025). Incremental modification in the existing approaches for affinity chromatographic enrichment of phosphoproteins improves their profile in liquid chromatography-tandem mass spectrometry analysis. Analytical Science Advances. 6(1):e202400058.
- 3. Joshi P, Kole L, Patil A, Singh A, Shetty R, Nair S, Chaturvedi P (2025). A retrospective study of lip carcinoma at a tertiary cancer centre. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.
- 4. Dinesan A, Singh M, Mehta P, Maitre P, Murthy V (2025). Acute enteritis with pelvic SBRT: Influence of bowel delineation methods. Clinical and Translational Radiation Oncology.
- 5. Sawant V, Mithun S, Jha AK, Rangarajan V (2025). Monte carlo simulation of characteristics of discovery NM/CT 670 pro SPECT system for routinely used diagnostic and therapeutic radionuclides. Journal of Nuclear Medicine Technology.
- 6. Dwivedi P, Barage S, Jha AK, Choudhury S, Rangarajan V (2025). Robustness of 18F-FDG PET radiomic features in lung cancer: Impact of advanced reconstruction algorithm. Journal of Nuclear Medicine Technology.
- 7. Gupta SK, Yadav S, Sharma D, Sandur SK, Khattry N, Goda JS, Gota V(2025). Effect of the radioprotector chlorophyllin on graft versus leukemia response in experimental allogeneic hematopoietic stem cell transplantation. Journal of Ayurveda and Integrative Medicine. 16(2):101109
- 8. Bajpai J, Sarkar L, Rath S, Pawar A, Chandrashekharan A, Panda G, Jakar D, Ghosh J, Laskar S, Rekhi B, Khanna N, Jose J, Ramdawar M, Purandare N, Bhargava P, Chakrabarty N, Gala K, Kembhavi Y, Rangarajan V, Banavali S, Gupta S (2025). Prognostic modeling for bone sarcomas based on a large prospective cohort from a tertiary care cancer center in India. JCO Global Oncology.
- 9. Cortes J, Kim D-W, Saikia T, Khattry N, Rathnam K, Alvarado Y, Hannah G, Tantravahi S, Apperley J, Charbonnier A, García-Gutiérrez V, Lucchesi A, Dima D, Illés Á, Popav V, Abruzzese E, Nag A, Apte S, Badar T, Yao S-L, Saxena U, Sreenivasan J, Inamdar S, Chimote G, Nicolini F (2025). Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial. Lancet Haematology.

Video of the Week
Upcoming Events
22-23 February 2025
ICGC2025 Conference (Choksi Auditorium, TMH): 22-23 Feb 2025
Pre-conference NGS Hands on Workshop at ACTREC Navi Mumbai: 20-21st February 2025
Pre-conference Genetic Counselling (GC) Workshop at TMH, Mumbai: 20-21st February 2025.
March 21-23, 2025
At Hotel Crowne Plaza, Rohini, New Delhi
Do You Know?
In 2011, The identification of abundant long noncoding RNAs (lncRNAs) in humans catalyzed the characterization of their role in cancer.

Cancer News
News-Medical, 03/02/2025
This study aimed to assess the safety and feasibility of using SABR in cancer patients with polymetastatic disease where the cancer has spread to more than 10 spots in multiple organs throughout the body – who have very few drug treatment options available to them...
EurekAlert, 04/02/2025
In the study, the researchers focused on medulloblastomas, a common childhood brain tumor. Through advanced tools like CRISPR gene editing, single-cell RNA sequencing, and collaborative drug testing, the study identified the OLIG2 protein as a key regulator of the tumor’s growth transitions...
MedicalXpress, 05/02/2025
RAD51 is a protein involved in homologous recombination repair (HRR) alterations. Developed in-house by Serra's laboratory, the RAD51 assay is based on the detection of this protein as a functional biomarker to potentially enhance the stratification of patients with cancer associated with deficiency...
© 2025 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)